Takeda Pharmaceutical Co Ltd SEC Filings

Takeda Pharmaceutical Company Limited is revising its FY2025 consolidated financial statements to reflect provisions for legal proceedings following a recent AMITIZA antitrust jury verdict in the United States. The company has filed a revised Earnings Report with the Tokyo Stock Exchange and updated related FY2025 financial materials.

Takeda emphasizes that these provisions do not change its Core financial results for FY2025, its FY2026 financial forecast, or Management Guidance. The company also highlights that its fundamental business momentum remains intact, supported by three major product launches planned in the next 12 months.

The year-end dividend for FY2025 remains at JPY 100 per share, and the annual dividend forecast for FY2026 stays at JPY 204 per share. The event occurred after the audit report date under the Japanese Companies Act, so the related provisions are not reflected in those statutory FY2025 financial statements.

Takeda Pharmaceutical Company Limited plans to withdraw its existing Japanese Shelf Registration Statement for new shares and file a new shelf in Japan covering issuance of common stock or disposition of treasury shares. The new shelf supports ongoing grants under Takeda’s Long Term Incentive Plan (LTIP) for employees.

The scheduled issue period runs from June 9, 2026 to June 8, 2027, with a maximum aggregate issue amount of up to JPY 240 billion. Takeda states that transactions under this shelf are tied to the LTIP and are not intended to raise funds, but to deliver shares as compensation. Share dilution from vesting of the LTIP and earlier management stock grant systems in the fiscal year ending March 31, 2027 is expected to be around 1.1% in total.

Takeda Pharmaceutical Company Limited plans to withdraw its existing Japanese Shelf Registration Statement for new shares and file a new shelf in Japan covering issuance of common stock or disposition of treasury shares. The new shelf supports ongoing grants under Takeda’s Long Term Incentive Plan (LTIP) for employees.

The scheduled issue period runs from June 9, 2026 to June 8, 2027, with a maximum aggregate issue amount of up to JPY 240 billion. Takeda states that transactions under this shelf are tied to the LTIP and are not intended to raise funds, but to deliver shares as compensation. Share dilution from vesting of the LTIP and earlier management stock grant systems in the fiscal year ending March 31, 2027 is expected to be around 1.1% in total.

Takeda Pharmaceutical Company Limited is convening its 150th Annual General Meeting of Shareholders on June 24, 2026 in Osaka and via internet livestream. Shareholders will vote on a year-end dividend, director elections, a substitute Audit and Supervisory Committee member, and director bonuses.

For the year ended March 31, 2026, Takeda reported revenue of JPY 4,505.7 billion, down 1.7%, mainly from U.S. generic competition to ADHD drug VYVANSE, while its other five key business areas grew. Net profit rose sharply to JPY 192.0 billion, and core operating profit was stable at JPY 1,172.5 billion, lifting core EPS to JPY 517.

The Board proposes a year-end dividend of JPY 100 per share, bringing the annual dividend to JPY 200, 4 yen higher than the prior year, and up to JPY 260 million in bonuses for two internal directors, reflecting lower KPI payouts. Takeda guides fiscal 2026 revenue to JPY 4,640.0 billion (+3.0%) but expects lower reported EPS of JPY 104.26 and core EPS of JPY 472 as it reinvests in launches and absorbs a higher tax rate.

Takeda Pharmaceutical Company Limited is convening its 150th Annual General Meeting of Shareholders on June 24, 2026 in Osaka and via internet livestream. Shareholders will vote on a year-end dividend, director elections, a substitute Audit and Supervisory Committee member, and director bonuses.

For the year ended March 31, 2026, Takeda reported revenue of JPY 4,505.7 billion, down 1.7%, mainly from U.S. generic competition to ADHD drug VYVANSE, while its other five key business areas grew. Net profit rose sharply to JPY 192.0 billion, and core operating profit was stable at JPY 1,172.5 billion, lifting core EPS to JPY 517.

The Board proposes a year-end dividend of JPY 100 per share, bringing the annual dividend to JPY 200, 4 yen higher than the prior year, and up to JPY 260 million in bonuses for two internal directors, reflecting lower KPI payouts. Takeda guides fiscal 2026 revenue to JPY 4,640.0 billion (+3.0%) but expects lower reported EPS of JPY 104.26 and core EPS of JPY 472 as it reinvests in launches and absorbs a higher tax rate.

Takeda Pharmaceutical Company Limited provides detailed notes to its consolidated and unconsolidated financial statements prepared under IFRS for the year ended March 31, 2026. Consolidated revenue from contracts with customers was JPY 4,505,720 million, driven mainly by gastroenterology, rare diseases, plasma-derived therapies and neuroscience.

Impairment losses on intangible assets associated with products totaled JPY 129,266 million, including JPY 58,173 million for the gamma delta T-cell therapy platform and associated oncology programs and JPY 31,877 million for ALUNBRIG. Other operating expenses were JPY 156,435 million, including restructuring expenses of JPY 70,818 million and a valuation reserve for pre-launch inventories of JPY 50,984 million.

Equity attributable to owners of the Company per share was JPY 4,920.50 and basic earnings per share were JPY 121.75. During the year, Takeda completed a share repurchase program, acquiring a total of 23,367 thousand shares for JPY 99,956 million, and paid cash dividends of JPY 313,233 million, with an additional JPY 158,494 million dividend proposed. The notes also detail goodwill of JPY 5,809,010 million, provisions for litigation of JPY 13,204 million, and a comprehensive breakdown of revenue by product and region.

Takeda Pharmaceutical Company Limited provides detailed notes to its consolidated and unconsolidated financial statements prepared under IFRS for the year ended March 31, 2026. Consolidated revenue from contracts with customers was JPY 4,505,720 million, driven mainly by gastroenterology, rare diseases, plasma-derived therapies and neuroscience.

Impairment losses on intangible assets associated with products totaled JPY 129,266 million, including JPY 58,173 million for the gamma delta T-cell therapy platform and associated oncology programs and JPY 31,877 million for ALUNBRIG. Other operating expenses were JPY 156,435 million, including restructuring expenses of JPY 70,818 million and a valuation reserve for pre-launch inventories of JPY 50,984 million.

Equity attributable to owners of the Company per share was JPY 4,920.50 and basic earnings per share were JPY 121.75. During the year, Takeda completed a share repurchase program, acquiring a total of 23,367 thousand shares for JPY 99,956 million, and paid cash dividends of JPY 313,233 million, with an additional JPY 158,494 million dividend proposed. The notes also detail goodwill of JPY 5,809,010 million, provisions for litigation of JPY 13,204 million, and a comprehensive breakdown of revenue by product and region.

Takeda Pharmaceutical shares a letter from CEO-elect Julie Kim outlining recent progress and a two-horizon growth plan. For fiscal year 2025, Takeda reported core revenue of approximately 4.5 trillion yen (about $28.3 billion) and Core Operating Profit of about 1.17 trillion yen (about $7.4 billion), helped by growth in core in-line brands but partially offset by loss-of-exclusivity pressure.

The company highlights strong clinical results, including positive Phase 3 data for oveporexton and zasocitinib, regulatory submissions for oveporexton in narcolepsy type 1 and rusfertide in polycythemia vera, and preparation of filings for zasocitinib in psoriasis. Launches for oveporexton and rusfertide are targeted for the second half of 2026 and for zasocitinib in the first half of 2027.

Under “Horizon One,” Takeda plans substantial FY2026 growth investments, organizational changes and a transformation program while aiming to protect Core Operating Profit and maintain strong adjusted free cash flow. “Horizon Two” targets accelerated, sustainable growth driven by new blockbuster brands and an expansion of Core Operating Profit margin into the low-to-mid 30s percent range.

Takeda Pharmaceutical shares a letter from CEO-elect Julie Kim outlining recent progress and a two-horizon growth plan. For fiscal year 2025, Takeda reported core revenue of approximately 4.5 trillion yen (about $28.3 billion) and Core Operating Profit of about 1.17 trillion yen (about $7.4 billion), helped by growth in core in-line brands but partially offset by loss-of-exclusivity pressure.

The company highlights strong clinical results, including positive Phase 3 data for oveporexton and zasocitinib, regulatory submissions for oveporexton in narcolepsy type 1 and rusfertide in polycythemia vera, and preparation of filings for zasocitinib in psoriasis. Launches for oveporexton and rusfertide are targeted for the second half of 2026 and for zasocitinib in the first half of 2027.

Under “Horizon One,” Takeda plans substantial FY2026 growth investments, organizational changes and a transformation program while aiming to protect Core Operating Profit and maintain strong adjusted free cash flow. “Horizon Two” targets accelerated, sustainable growth driven by new blockbuster brands and an expansion of Core Operating Profit margin into the low-to-mid 30s percent range.

Takeda Pharmaceutical Company details its FY2025 executive compensation, linking pay closely to financial, R&D and shareholder return metrics. Short-term incentive payouts were based on corporate KPIs, resulting in a Corporate KPI payout multiple of 72.8%, so FY2025 bonuses are more than 40% lower than FY2024.

Long-term Performance Share Unit awards for FY2023–2025 achieved a payout multiple of 130.9%, driven by strong three-year accumulated Core Revenue and Core Operating Profit and an R&D KPI score of 147.7%. Takeda reports a three-year Total Shareholder Return of 51.0%, ranking 7th of 15 peers, and confirms a CEO succession in June 2026, with Julie Kim slated to succeed Christophe Weber.

Takeda Pharmaceutical Company details its FY2025 executive compensation, linking pay closely to financial, R&D and shareholder return metrics. Short-term incentive payouts were based on corporate KPIs, resulting in a Corporate KPI payout multiple of 72.8%, so FY2025 bonuses are more than 40% lower than FY2024.

Long-term Performance Share Unit awards for FY2023–2025 achieved a payout multiple of 130.9%, driven by strong three-year accumulated Core Revenue and Core Operating Profit and an R&D KPI score of 147.7%. Takeda reports a three-year Total Shareholder Return of 51.0%, ranking 7th of 15 peers, and confirms a CEO succession in June 2026, with Julie Kim slated to succeed Christophe Weber.

Takeda Pharmaceutical Company Limited plans to revise its FY2025 consolidated IFRS earnings report after a jury verdict in the AMITIZA® (lubiprostone) antitrust litigation on May 18, 2026 was determined to be an adjusting subsequent event. The company is still assessing the financial impact.

Because the verdict came after the May 12, 2026 audit report date under the Japanese Companies Act, it will not change the Japanese statutory consolidated or unconsolidated financial statements for the year ended March 31, 2026 included in the shareholder meeting materials. Takeda intends to file a revised Earnings Report with the Tokyo Stock Exchange and update other FY2025 financial materials on its website once the impact is finalized.

The company states that it does not expect its FY2026 financial forecast or Management Guidance to be materially impacted, though it may revise these once the assessment is complete.

Takeda Pharmaceutical Company Limited plans to revise its FY2025 consolidated IFRS earnings report after a jury verdict in the AMITIZA® (lubiprostone) antitrust litigation on May 18, 2026 was determined to be an adjusting subsequent event. The company is still assessing the financial impact.

Because the verdict came after the May 12, 2026 audit report date under the Japanese Companies Act, it will not change the Japanese statutory consolidated or unconsolidated financial statements for the year ended March 31, 2026 included in the shareholder meeting materials. Takeda intends to file a revised Earnings Report with the Tokyo Stock Exchange and update other FY2025 financial materials on its website once the impact is finalized.

The company states that it does not expect its FY2026 financial forecast or Management Guidance to be materially impacted, though it may revise these once the assessment is complete.

Takeda Pharmaceutical Company Limited reports that a U.S. federal jury in Massachusetts returned a verdict against the company in AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs USD 884,943,990 in single damages. This includes USD 474,897,965 for a wholesaler class and USD 346,837,646 for individual retailers, which are subject to automatic trebling under U.S. antitrust law upon entry of judgment. Damages for an end payor class remain subject to further court proceedings.

Takeda states it will vigorously pursue post-trial motions and an appeal and notes the verdict is not enforceable until judgment is entered. The company is assessing a provision to recognize in its consolidated financial statements for the fiscal year ended March 31, 2026 and plans to revise and re-file its FY2025 earnings and related materials once the amount is determined. Takeda indicates this outcome will not affect FY2025 Core financial results and does not expect a material impact on its FY2026 financial forecast or Management Guidance, other than potential changes to adjusted free cash flow depending on the amount and timing of any payment.

Takeda Pharmaceutical Company Limited reports that a U.S. federal jury in Massachusetts returned a verdict against the company in AMITIZA (lubiprostone) antitrust litigation, awarding plaintiffs USD 884,943,990 in single damages. This includes USD 474,897,965 for a wholesaler class and USD 346,837,646 for individual retailers, which are subject to automatic trebling under U.S. antitrust law upon entry of judgment. Damages for an end payor class remain subject to further court proceedings.

Takeda states it will vigorously pursue post-trial motions and an appeal and notes the verdict is not enforceable until judgment is entered. The company is assessing a provision to recognize in its consolidated financial statements for the fiscal year ended March 31, 2026 and plans to revise and re-file its FY2025 earnings and related materials once the amount is determined. Takeda indicates this outcome will not affect FY2025 Core financial results and does not expect a material impact on its FY2026 financial forecast or Management Guidance, other than potential changes to adjusted free cash flow depending on the amount and timing of any payment.

Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.

Takeda Pharmaceutical Co. Ltd. filed an initial Form 3 for executive Jennifer Marie Smoter, who serves as Chief Communications & Government Officer. The filing does not report any insider transactions or holdings; it simply establishes her status as a reporting person for future disclosures.